Frequency and genotype distribution of high-risk human papilloma virus types in Karabuk province, Turkey: A hospital based cross-sectional study

Aim: In this cross-sectional study, we aimed to determine the prevalence and genotype distribution of high-risk human papillomavirus(HPV; HR-HPV) infection in patients admitted to the gynecology and obstetrics outpatient clinics of Karabuk University Training andResearch Hospital.Material and Methods: A total of 402 women aged 18–65 years who were admitted to the gynecology and obstetrics Clinic, KarabukUniversity Training and Research Hospital, between October 2016 and June 2019 were included. The presence of HR-HPV andgenotyping of HPV were investigated using real-time polymerase chain reaction in cervical swab samples.Results: HR-HPV infection was found in 23.9% of women. HR-HPV positivity was detected most commonly in the age group of20–29 years. Regarding genotype distribution among HPV-positive women, the genotypes that included multiple HR-HPV infections(mixed HR-HPV) were the most common genotype (38.5%), followed by HPV-16 (13.1%) and HPV-52 (9.8%).Conclusion: Prevalence of HR-HPV infection was found to be high in our region, with the most commonly observed genotypes beingthose containing mixed HR-HPV. We believe that these results would be helpful during the selection of primary and secondarypreventive measures for cervical cancer while planning vaccination and screening programs

PDF

___

1. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30:12-23.
2. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health 2005;37:3-9.
3. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International journal of cancer 2007;121:621-32.
4. Sreedevi A, Javed R, Dinesh A. Epidemiology of cervical cancer with special focus on India. International journal of women’s health 2015;7:405.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
6. Franceschi S, Plummer M, Clifford G, et al. International Agency for Research on Cancer Human Papillomavirus Prevalence Surveys Study Group. Differences in the risk of cervical cancer and human papillomavirus infection by education level. Br J Cancer 2009;101: 865-70.
7. Xu HH, Wang K, Feng XJ, et al. Prevalence of human papillomavirus genotypes and relative risk of cervical cancer in China: a systematic review and metaanalysis. Oncotarget 2018;9:15386.
8. Lagheden C, Eklund C, Lamin H, et al. Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. British journal of cancer 2018;118:1377.
9. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018;68:394-424.
10. Dursun P, Ayhan A, Mutlu L, Çağlar M, Haberal A, Güngör T, Güner H. HPV Types in Turkey: Multicenter Hospital Based Evaluation of 6388 Patients in Turkish Gynecologic Oncology Group Centers. Turkish J Pathology 2013;29:210-6.
11. Taskin MI, Adali E, Yavuz T, et al. HR-HPV Prevelance and Types in Balikesir. JCAM 2015;3783.
12. Aydogan S, Yazgan A, Tas EE, et al. The presence and distribution of high risk HPV types in simultaneous cervical cytology samples. Turkish Bulletin of Hygiene and Experimental Biology 2018;75:13-20.
13. Oz ZS, Demirezen S, Kuzey GM, et al. Cytologic and clinical evaluation of human papillomavirus in women underwent routine gynecologic examination. Gynecology Obstetrics & Reproductive Medicine 2009;15:94-9.
14. Tuncer S, Başaran M, Ustaçelebi S, et alG. High-risk human papilloma virus (HPV) infection determined by Hybrid Capture II assay in a Turkish university hospital outpatient clinic. Gynecology Obstetrics & Reproductive Medicine 2006;12:129-34.
15. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87.
16. Bosch FX, Robles C, Diaz M, Arbyn M, Baussano I, Clavel C, et al. HPV FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2016;13:119-32.
17. de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International journal of cancer 2017; 141:664-70.
18. Gultekin M, Kucukyildiz I, Karaca MZ, et al. Trends of gynecological cancers in Turkey: toward Europe or Asia?. International Journal of Gynecologic Cancer 2017;27:1525-33.
19. Bruni L, Diaz M, Castellsagué M, et al. Cervical human papillomavirus prevalence in 5 continents: metaanalysis of 1 million women with normal cytological findings. Journal of Infectious Diseases 2010;202: 1789-99.
20. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. Jama 2007;297:813-9.
21. Wang X, Zeng Y, Huang X, et al. Prevalence and Genotype Distribution of Human Papillomavirus in Invasive Cervical Cancer, Cervical Intraepithelial Neoplasia, and Asymptomatic Women in Southeast China. BioMed research international, 2018.
22. Chokunonga E, Borok MZ, Chirenje ZM, et al. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991–2010. International journal of cancer 2013;133:721-9.
23. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. International journal of cancer 2006;119:2677-84.
24. De Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. The Lancet infectious diseases 2007;7:453-9.
25. Yu L. Rural–Urban and Racial/Ethnic Disparities in Invasive Cervical Cancer Incidence in the United States, 2010–2014. Preventing chronic disease 2019; 16.
26. Althoff KN, Paul P, Burke AE, et al. Correlates of cervicovaginal human papillomavirus detection in perimenopausal women. J Womens Health (Larchmt) 2009;18:1341-6.
27. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26:1-16.
28. Passmore JA, Morroni C, Shapiro S, Williamson AL, Hoffman M. Papanicolaou smears and cervical inflammatory cytokine responses. J Inflamm (Lond) 2007;4:8.
29. Luttmer R, De Strooper LM, Steenbergen RD, et al. Management of high-risk HPV-positive women for detection of cervical (pre) cancer. Expert review of molecular diagnostics 2016;16:961-74.
30. Beachler DC, Kreimer AR, Schiffman M, et al. Multisite HPV 16/18 vaccine efficacy against cervical, anal, and oral hpv infection. J Natl Cancer Inst 2016;108.
31. Berenson AB, Laz TH, Rahman M. Reduction in Vaccine-Type Human Papillomavirus Prevalence Among Women in the United States, 2009-2012. J Infect Dis 2016;214:1961.